Dr. Dupuis is scientist turned biotech analyst who has leveraged his scientific expertise and financial knowledge to lead a career in biotech finance.

Dylan has spent a majority of his professional career within the financial industry, focusing on biotech. Most recently, he served as Senior Analyst, Managing Director, at Roth MKM, leading SMID-cap biotech research coverage. Prior to this work, he was a research associate at B. Riley FBR, and served as VP of Equity Research at SVB Leerink. In these sell-side research roles, Dr. Dupuis has launched, led, or helped lead coverage on nearly 50 SMID-cap biotech companies, with a primary focus on immunology and metabolic diseases, but with broader exposure to other therapeutic areas including oncology, neurology, rare diseases, and regenerative medicine. He also applied his biotech finance expertise while serving as a Senior Analyst at healthcare focused Altium Capital. While there, Dr. Dupuis co-managed a ~$100MM healthcare portfolio that consistently outperformed the XBI over two years. As part of his responsibilities, Dr. Dupuis led due diligence on ~120 SMID-cap biotech companies in therapeutic areas that included immunology, metabolic diseases, targeted oncology, and gene therapy. He began his finance career at Seven Points Capital, first as a trader and later as an assistant branch manager in charge of hiring and training new traders for the firm’s first branch office. In this role, he helped the branch office achieve seven consecutive profitable quarters while also significantly expanding employee headcount and managing a $1MM proprietary trading account. 

Dr. Dupuis received his BS degree in Biology and Chemistry from Lycoming College and then earned his PhD in Molecular Biology from Lehigh University. While at Lehigh University, he led research into the regulatory impact of A-to-I RNA editing on non-protein coding RNA, showing RNA editing similarly occurs in RNA derived from repetitive elements independent of the RNA polymerase subtype responsible for transcription. Following his graduate studies, Dr. Dupuis completed a Research Fellowship at the Center for Vascular Biology Research (CVBR) at Beth Israel Deaconess Medical Center, Harvard Medical School. While at the CVBR, he secured independent NIH funding that supported research into the regulatory role of the PI3K/AKT/FOXO1 pathway in early cardiovascular development and cardiovascular maintenance. He also spearheaded preliminary research into ERG-regulated genes encoding for lncRNA, using a stem cell model of early vascular development to demonstrate a regulatory effect of these lncRNA on early markers of endothelial cell differentiation.

Dupuis’ career includes over 10 years of experience in finance in roles ranging from trader to research Managing Director, amassing experience on both the buy- and sell-sides. His deep-dive fundamental approach to biotech analysis is differentiated by its focus on understanding the causal relationship between clinical trial data and market access within evolving treatment paradigms.